Preparing for an MQSA Inspection: What Mammography Facilities Need to Know

Why MQSA Inspections Matter Now More Than Ever

Annual MQSA inspections are a cornerstone of the federal quality standards program for mammography. Required under 42 U.S.C. 263b(g)(1)(E), these inspections provide independent verification that certified mammography facilities are meeting the requirements established by the Mammography Quality Standards Act.

The 2023 MQSA Final Rule (88 FR 15126), which became fully effective on September 10, 2024, represents the most comprehensive regulatory update since 1997. It modernized definitions, strengthened enforcement, added mandatory breast density notification requirements, and aligned the regulations with current digital mammography and digital breast tomosynthesis practice.

For mammography facilities, this regulatory update makes inspection readiness more critical than ever. Documentation, workflows, patient communication, and quality assurance processes must now reflect the updated framework — and inspectors are actively verifying compliance with the new requirements.

The FDA Guidance Vacuum

Before the 2024 regulatory update, the FDA maintained publicly available guidance materials to help facilities prepare for MQSA inspections. After the 2023 Final Rule went into effect, that older guidance was retired — and a comprehensive updated replacement has not been published in the same format.

This creates a real challenge for breast imaging teams preparing for their annual inspection. The regulations changed significantly. The old checklists no longer map cleanly to the current requirements. And the FDA's current MQSA Program website, while authoritative, does not provide the step-by-step preparation guidance that facilities need.

Mammologix developed this guide to fill that gap. It is based on direct experience supporting mammography facilities, comprehensive review of 21 CFR Part 900, and firsthand knowledge of what MQSA inspectors look for in practice.

---

The MQSA Organizational Framework

Understanding the structure of the MQSA program helps facilities know who is responsible for what and where accountability lies.

Three Parties Responsible for Your Certificate

Party	Role
FDA (DMQS)	Sets regulations, certifies facilities, conducts inspections, takes enforcement action
Accreditation Body (ACR or state programs)	Reviews image quality and QC compliance, grants accreditation required for FDA certification
Medical Physicist	Conducts annual survey of mammography equipment, reviews QC records

The Annual Compliance Cycle

Every certified mammography facility must complete the following each year:

• Maintain accreditation with an FDA-approved accreditation body
• Pass an annual medical physicist equipment survey
• Undergo an annual FDA MQSA inspection
• Pay applicable inspection fees
• Correct any deficiencies identified during inspections or surveys

FDA inspectors work from a standardized inspection protocol aligned with 21 CFR Part 900. They systematically review facility documentation, records, and processes against the current regulatory requirements.

---

What Inspectors Look For: The Eight Core Areas

Based on 21 CFR Part 900 and inspection experience, MQSA inspectors review eight areas. Preparation in each area is essential.

1. Facility Certification and Accreditation Status

What inspectors verify:

• Current FDA certificate is posted in the facility and visible to patients
• Accreditation is current and the accreditation body is FDA-approved
• Facility scope (units, modalities) matches what is certified

Common deficiencies:

• Certificate posted in a staff area rather than a patient-accessible location
• Accreditation documents are expired or not available on-site
• Equipment added to service without updating the certificate

Preparation checklist:

• FDA certificate is current and posted in a publicly visible location
• Accreditation certificate is current and on file
• All mammography units in service are listed on the certificate
• Contact information on file with FDA is current

---

2. Personnel Qualifications and Records

Personnel qualification tracking is one of the most inspection-intensive areas. Under 21 CFR §900.12(a)(1)–(a)(3), facilities must verify and document that all interpreting physicians, radiologic technologists, and medical physicists meet ongoing qualification requirements — not just at hire, but on a rolling basis.

Interpreting Physicians (21 CFR §900.12(a)(2)):

• Initial training: 3 months of training in mammography interpretation or equivalent
• Continuing education: 15 CME credits in mammography every 36 months
• Continuing experience: 960 mammograms interpreted every 24 months

Radiologic Technologists (21 CFR §900.12(a)(1)):

• Initial training: Completion of a mammography training program and documented competency
• Continuing education: 15 CEU credits in mammography every 36 months
• Continuing experience: 200 mammography examinations performed every 24 months

Medical Physicists (21 CFR §900.12(a)(3)):

• Must meet specific education, training, and experience requirements
• Must be surveying within their qualified modality (FFDM, DBT, screen-film)

Record retention under the 2024 Final Rule: Facilities must retain personnel qualification records for at least 24 months after an individual ceases to work at the facility. Employees now have the right to request copies of their own qualification records.

Preparation checklist:

• Personnel qualification files are current for all interpreting physicians
• Technologist qualification files are current for all RT staff
• Medical physicist qualification documents are on file
• CME/CEU tracking is up to date and verifiable
• Experience logs (case counts) are current and accurate
• Records include documentation supporting each qualification criterion

---

3. Equipment and Quality Control Records

Equipment requirements (21 CFR §900.12(b)): Under the 2024 Final Rule, all mammography equipment must have FDA premarket authorization. A change in mammography modality (e.g., adding DBT capability) is treated as a new mammography unit requiring accreditation for the new modality.

QC testing records: Inspectors will review QC records to confirm:

• Daily, weekly, monthly, and quarterly tests were performed on schedule
• All test results were within acceptable parameters or corrective actions were documented
• The medical physicist's annual survey was completed and signed off
• Corrective actions were completed and documented when QC tests failed

Preparation checklist:

• All QC logs are current through the inspection date
• Medical physicist annual survey report is on file and dated
• Equipment failure documentation and corrective action records are complete
• Modality on certificate matches modality in use

---

4. Medical Records and Reporting

This section covers some of the most significant changes in the 2024 Final Rule.

Written report requirements (21 CFR §900.12(c)(3)):

• The term "physician" has been replaced with "healthcare provider" in the regulations
• For assessments of "Suspicious" (Category D) or "Highly Suggestive of Malignancy" (Category E), the written report must be provided within 7 days of the examination
• All other cases must receive a report within 30 days

The FDA Imaging Assessment Categories (21 CFR §900.12(c)(1)): MQSA regulations define specific assessment language that must be used in mammography reports. The FDA recognizes nine imaging assessment categories — more than the BI-RADS® 0–6 shorthand commonly used in clinical settings:

Category	FDA Assessment Language
A	Negative
B	Benign
C	Probably Benign
D	Suspicious
E	Highly Suggestive of Malignancy
F	Known Biopsy-Proven Malignancy
G	Post-Procedure Mammogram for Marker Placement
Incomplete	Incomplete: Need additional imaging evaluation
Incomplete	Incomplete: Need prior mammograms for comparison

FDA inspectors reference imaging assessment categories — not BI-RADS® numbers. BI-RADS® is a registered trademark of the American College of Radiology.

Preparation checklist:

• Report templates use FDA-aligned assessment language
• 30-day lay letter process is documented and functioning
• 7-day urgent letter process is in place for Category D and E cases
• Letter logs track date sent, recipient, and assessment category

---

5. Breast Density Notification

The mandatory breast density notification requirement is entirely new under the 2024 Final Rule — the first federal breast density notification law in U.S. history. Every lay letter must now include density notification language specific to the patient's assigned density category.

The four FDA breast density categories with required language:

Category A — Almost Entirely Fatty:

"The breast tissue is almost entirely fatty. This does not affect the ability to find cancer with a mammogram."

Category B — Scattered Areas of Fibroglandular Density:

"The breast tissue has scattered areas of fibroglandular density. This does not significantly affect the ability to find cancer with a mammogram."

Category C — Heterogeneously Dense: Requires the FDA-specified heterogeneously dense paragraph plus the standardized informational paragraph about discussing results with a healthcare provider.

Category D — Extremely Dense: Requires the FDA-specified extremely dense paragraph plus the standardized informational paragraph.

Preparation checklist:

• Lay letter templates include density notification paragraphs for all four categories
• Density assignment is being documented per examination
• Letters use the FDA-required language, not paraphrased versions
• Staff are trained on density notification requirements

---

6. Medical Outcome Audit

The MQSA medical outcome audit is a required component of every certified facility's quality program under 21 CFR §900.12(f).

What the audit requires:

• A systematic tracking program that follows positive mammographic assessments to tissue diagnosis outcomes
• Calculation of standardized performance metrics: Recall Rate (AIR), Cancer Detection Rate (CDR), and Positive Predictive Values (PPV1, PPV2, PPV3)
• Physician-level and aggregate facility reporting
• Annual review and analysis
• Record retention until after the first annual inspection following the analysis period

Preparation checklist:

• Audit database is current through the inspection period
• Positive case log captures all required assessment categories
• Outcome data has been correlated for complete cases
• Annual analysis has been performed and documented
• Physician-specific metrics have been calculated and reviewed
• Audit summary reports are on file

---

7. Consumer Complaint Mechanism

Every certified facility must have a written consumer complaint mechanism available to patients (21 CFR §900.12(e)).

What inspectors verify:

• A written complaint procedure exists
• The procedure is available to patients
• Patient complaints are logged and tracked
• Complaints are reviewed and responded to

Preparation checklist:

• Written complaint procedure is in place
• Complaint information is accessible to patients
• Complaint log is current
• Any complaints received have been documented and addressed

---

8. Patient Records, Transfer, and Retention

Under the 2024 Final Rule (21 CFR §900.12(c)(4)), facilities must provide mammography records to a patient, their healthcare provider, or another facility within 15 days of a written request. The rule now also addresses digital record requirements and facility closure record access.

Preparation checklist:

• Record request and transfer process is documented
• Turnaround time for record requests is tracked
• Digital record storage and retrieval systems are operational
• Facility closure record access plan is in place if applicable

---

How to Prepare: Practical Steps

90 Days Before Your Inspection Window

1. Audit your personnel files — Go through every interpreting physician, technologist, and medical physicist file. Verify that continuing education and experience requirements are current. Identify anyone approaching a qualification deadline.

2. Review your QC logs — Are they current? Were corrective actions documented for any failed QC tests? Make sure the medical physicist's most recent survey report is on file.

3. Pull sample reports and lay letters — Review 10–20 reports and their corresponding lay letters. Verify assessment language, lay letter content, turnaround times, and density notification language.

4. Check your accreditation certificate — Confirm it is current and that all active units are covered.

30 Days Before

5. Run your audit data — Generate current AIR, CDR, and PPV reports. Verify your analysis documentation is complete.

6. Review complaint logs — Make sure all complaints are logged, responded to, and documented.

7. Stage your documentation — Organize the documents inspectors are most likely to request into a single accessible location. Inspector visits are time-limited; being able to produce records quickly matters.

Day of Inspection

8. Be cooperative and transparent — MQSA inspectors are verifying regulatory compliance, not conducting adversarial audits. Organized, forthcoming facilities tend to have smoother inspections.

9. Document everything discussed — After the inspection, document any items the inspector noted, any corrective actions discussed, and the expected follow-up timeline.

---

Deficiency Levels and Consequences

MQSA inspection findings are categorized by severity:

Level	Description	Response Required
Level 1	Deficiency that seriously compromises facility quality or patient safety	Immediate corrective action; may require temporary cessation of mammography
Level 2	Deficiency that compromises quality but not at Level 1 severity	Corrective action required; documented follow-up with FDA
Level 3	Minor deficiency not meeting Level 1 or 2 criteria	Corrective action recommended; documented

Repeated Level 2 or Level 1 deficiencies can result in escalating enforcement action up to and including certificate suspension or revocation.

---

Download the Full Inspection Preparation Guide

This article provides the essential framework. For the complete Mammologix MQSA Inspection Preparation Manual — including 12 templates, reference tables, and ready-to-use checklists — download the full guide below.

Download the Mammologix MQSA Inspection Preparation Guide (PDF)

---

References

• 21 CFR Part 900 — Mammography Quality Standards
• 88 FR 15126 — MQSA Final Rule (2023), Docket No. FDA-2013-N-0134, RIN 0910-AH04
• U.S. Food and Drug Administration, MQSA Program: https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program
• U.S. Food and Drug Administration, MQSA Inspection Resources: https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/mqsa-inspection-resources

---

BI-RADS® is a registered trademark of the American College of Radiology.